BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28871028)

  • 1. The role of pragmatism in explaining heterogeneity in meta-analyses of randomised trials: a protocol for a cross-sectional methodological review.
    Aves T; Allan KS; Lawson D; Nieuwlaat R; Beyene J; Mbuagbaw L
    BMJ Open; 2017 Sep; 7(9):e017887. PubMed ID: 28871028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying the PRECIS-2 tool for self-declared 'pragmatic' acupuncture trials: protocol for a systematic review.
    Lim J; Lee H; Kim YS
    BMJ Open; 2022 Apr; 12(4):e052861. PubMed ID: 35414545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study characteristics impacted the pragmatism of randomized controlled trial published in nursing: a meta-epidemiological study.
    Devos F; Foissac F; Bouazza N; Ancel PY; Tréluyer JM; Chappuy H
    J Clin Epidemiol; 2019 Dec; 116():18-25. PubMed ID: 31374332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do randomized controlled nursing trials have a pragmatic or explanatory attitude? Findings from the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool exercise.
    Palese A; Bevilacqua MG; Dante A;
    J Nurs Res; 2014 Sep; 22(3):216-20. PubMed ID: 25111115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Dal-Ré R; Janiaud P; Ioannidis JPA
    BMC Med; 2018 Apr; 16(1):49. PubMed ID: 29615035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of meta-analytic methods for synthesizing evidence from explanatory and pragmatic trials.
    Sajobi TT; Li G; Awosoga O; Wang M; Menon BK; Hill MD; Thabane L
    Syst Rev; 2018 Jan; 7(1):19. PubMed ID: 29370830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
    Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
    Trials; 2013 Apr; 14():115. PubMed ID: 23782862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pragmatic vs. explanatory: an adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice.
    Koppenaal T; Linmans J; Knottnerus JA; Spigt M
    J Clin Epidemiol; 2011 Oct; 64(10):1095-101. PubMed ID: 21474282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRECIS-2 for retrospective assessment of RCTs in systematic reviews.
    Zwarenstein M; Thorpe K; Treweek S; Loudon K
    J Clin Epidemiol; 2020 Oct; 126():202-206. PubMed ID: 32565215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRECIS-2 analysis of pragmatic acupuncture trials: a systematic review.
    Lim J; Lee H; Kim YS
    BMC Complement Med Ther; 2024 May; 24(1):181. PubMed ID: 38702632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.
    Dal-Ré R
    Eur J Clin Pharmacol; 2021 Apr; 77(4):539-546. PubMed ID: 33106910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are trials of psychological and psychosocial interventions for schizophrenia and psychosis included in the NICE guidelines pragmatic? A systematic review.
    Gastaldon C; Mosler F; Toner S; Tedeschi F; Bird VJ; Barbui C; Priebe S
    PLoS One; 2019; 14(9):e0222891. PubMed ID: 31550279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of Pragmatic and Explanatory Trials.
    Mbuagbaw L; Aves T
    Methods Mol Biol; 2022; 2345():147-158. PubMed ID: 34550589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades.
    Sepehrvand N; Alemayehu W; Das D; Gupta AK; Gouda P; Ghimire A; Du AX; Hatami S; Babadagli HE; Verma S; Kashour Z; Ezekowitz JA
    JAMA Cardiol; 2019 Nov; 4(11):1122-1128. PubMed ID: 31473763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
    Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
    J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
    Sharma T; Qamar I; Zwarenstein M
    J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
    Bratton DJ; Nunn AJ; Wojnarowska F; Kirtschig G; Sandell A; Williams HC
    Trials; 2012 Apr; 13():50. PubMed ID: 22540678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of the "Pragmatism" of Pragmatic Critical Care Trials.
    Palakshappa JA; Gibbs KW; Lannan MT; Cranford AR; Taylor SP
    Crit Care Explor; 2022 Jul; 4(7):e0738. PubMed ID: 35923590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.